Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of 10-1074-LS alone and with 3BNC117-LS in HIV
NCT03554408Phase 1Completed
- Sponsor
- The Rockefeller University
- Start
- Jun 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zinlirvimab in human immunodeficiency virus type 1 infection (HIV-1) (14 arms), sponsored by The Rockefeller University. Primary endpoints: Number of participants with adverse events at 2 weeks, Elimination half-life (t1/2) of 10-1074-LS and 4 more. Started Jun 2018; status: completed.
02
Drugs
zinlirvimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03554408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554408.